A Phase 2 interventional study of Obeldesivir and Obeldesivir Placebo in RSV Infection, sponsored by Gilead Sciences. Terminated at 121 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Respiratory Syncytial Virus Infections with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · United States.
Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, this one is the 51st largest by enrollment of the 122 interventional ones that give a count, is one of 13 that started in 2024, is one of 28 in phase 2, and was the 133rd registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →10 of the 145 studies in Respiratory Syncytial Virus Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Shionogi · Sites in United States, Argentina, Bulgaria and 5 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, South Africa and 1 more country
Ages 0+ · Healthy volunteers
Clover Biopharmaceuticals USA, LLC · Sites in United States
Ages 60–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 40 · Phase 3 29 · Phase 4 3
First in 1997; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 88 across the 122 interventional studies, 300 across the 23 observational. Of the 127 that completed or were terminated, 61 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
106 of 145 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 8 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
5 of the studies in Respiratory Syncytial Virus Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026749Phase 3University of Alabama at BirminghamAzithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children | 2027-07-01 |
| NCT07214571ShionogiA Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | 2026-12-30 |
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
| NCT06686654Sanofi Pasteur, a Sanofi CompanyStudy of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | 2027-01-18 |
| NCT06817889Fred Hutchinson Cancer CenterRemdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster.
The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Key Inclusion Criteria:
Exhibits at least 1 of the following risk factors for severe RSV disease:
One or more of the following chronic lung diseases:
New onset or increased from baseline of ≥ 2 of the following signs and or/symptoms, and at least 1 sign/symptom of moderate severity at screening, and onset ≤ 3 days before randomization.
RSV vaccine status:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ODV 700 mg twice on Day 1, followed by ODV 350 mg twice daily on Days 2 to 5.
Drug: Obeldesivir
Participants will receive placebo-to-match (PTM) ODV twice daily for 5 days.
Drug: Obeldesivir Placebo
Tablet administered orally
Also known as: GS-5245
Tablet administered orally
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15
RiiQ symptom scale is 13-item questionnaire (6 symptoms related to upper \& lower respiratory tract \& 7 systemic symptoms).Targeted RSV symptoms are 6 respiratory symptoms: nasal congestion, sore throat, cough, expectoration, shortness of breath \& wheezing.Each symptom is rated on scale of None, Mild, Moderate \& Severe.Alleviation of targeted RSV symptoms was defined as for 2 consecutive assessments: non-preexisting symptoms scored was None or Mild; pre-existing symptoms that were present but not worse at baseline scored same or below;\& pre-existing symptoms that were worse at baseline improved at least one scale grade level. Time to alleviation of targeted RSV symptoms by Day 15 for participants with symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time.For participants who completed or discontinued study by Day 15 without symptom alleviation (censored),time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.
Time frame: Up to Day 15
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.
Time frame: Up to 5 days plus 30 days
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point up to the date of the last dose of study drug plus 30 days. The Division of AIDS (DAIDS) Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1: mild, Grade 2: moderate, Grade 3: severe, and Grade 4: potentially life-threatening. Percentage are rounded off.
Time frame: Up to 5 days plus 30 days
Percentage of Participants Who Experienced Serious Adverse Events
A serious adverse event (SAEs) is defined as an event that, at any dose, results in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentage was rounded off.
Time frame: Up to 5 days plus 30 days
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation
TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.
Time frame: Up to 5 days plus 30 days
Time to Sustained Alleviation of Targeted RSV Symptoms as Measured by RiiQ Through Day 15
RiiQ and targeted RSV symptoms are defined in Outcome Measure #1. Each symptom is rated on scale of None, Mild, Moderate, \& Severe. Sustained alleviation of targeted RSV symptoms was defined similarly to alleviation of targeted RSV symptoms but for 3 consecutive assessments. Time to sustained alleviation of targeted RSV symptoms by Day 15 for participants with sustained symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed or discontinued study by Day 15 without sustained symptom alleviation (censored), time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.
Time frame: Up to Day 15
Time to RSV-Related Lower Respiratory Tract Infection (LRTI) Through Day 29
RiiQ is defined in Outcome Measure #1. Lower Respiratory Tract (LRT) symptoms included cough, expectoration, shortness of breath, and wheezing. Based on RiiQ, RSV-related LRTI was defined as \>=2 of the following symptoms, 1 of which must be reported as at least 'moderate' severity: new or increased cough, new or increased wheezing, new or increased shortness of breath, new or increased expectoration and participant has not met alleviation endpoints. The time to RSV-related LRTI by Day 29 for participants with RSV-related LRTI, was calculated as date/time of meeting LRTI definition minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without RSV-related LRTI (censored), time was calculated as last date/time on which RiiQ was assessed minus the first dose date/time.
Time frame: Up to Day 29
Time to RSV-Related Hospitalization or All-Cause Death Through Day 29
RSV-related hospitalization is defined as ≥ 24 hours of acute care for a reason related to RSV, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with RSV. RSV relatedness was determined by investigator. KM estimates were used in analysis.
Time frame: Up to Day 29
Time to RSV-Related Medically Attended Visit or All-Cause Death Through Day 29
Medically attended visits (MAV) are defined as any interactions with health care professionals other than study staff or designees, including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. RSV relatedness was determined by the investigator. KM estimates were used in analysis.
Time frame: Up to Day 29
RSV Viral Load At Baseline
The RSV viral load results were obtained from UTM (universal transport medium) nasal swab samples collected at Baseline.
Time frame: Baseline
Change From Baseline in RSV Viral Load Through Day 3
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 3.
Time frame: Baseline, Day 3
Change From Baseline in RSV Viral Load Through Day 5
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 5.
Time frame: Baseline, Day 5
Change From Baseline in RSV Viral Load Through Day 7
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 7.
Time frame: Baseline, Day 7
Change From Baseline in RSV Viral Load Through Day 10
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 10.
Time frame: Baseline, Day 10
Change From Baseline in RSV Viral Load Through Day 15
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 15.
Time frame: Baseline, Day 15
Pharmacokinetic (PK) Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir
AUCtau is defined as area under the plasma concentration-time curve during a dosing interval.
Time frame: Day 5: Pre-dose and at multiple timepoints (up to 12 hours) post-dose
PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir
Ctrough is defined as the concentration at the end of the dosing interval.
Time frame: Day 5 (predose)
PK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir
Cmax is defined as the maximum observed concentration of drug in plasma.
Time frame: Day 1 (At multiple timepoints [up to 4 hours] post-dose); Day 5 (Pre-dose and at multiple timepoints [up to 4 hours] post-dose)
Participants were enrolled at study sites in the United States.
| Milestone | Obeldesivir | Placebo |
|---|---|---|
| Started | 75 | 75 |
| Completed | 74 | 72 |
| Not completed | 1 | 3 |
| Withdrew: Randomized but never treated | 1 | 1 |
| Withdrew: Withdrew consent | 0 | 2 |
RiiQ symptom scale is 13-item questionnaire (6 symptoms related to upper \& lower respiratory tract \& 7 systemic symptoms).Targeted RSV symptoms are 6 respiratory symptoms: nasal congestion, sore throat, cough, expectoration, shortness of breath \& wheezing.Each symptom is rated on scale of None, Mild, Moderate \& Severe.Alleviation of targeted RSV symptoms was defined as for 2 consecutive assessments: non-preexisting symptoms scored was None or Mild; pre-existing symptoms that were present but not worse at baseline scored same or below;\& pre-existing symptoms that were worse at baseline improved at least one scale grade level. Time to alleviation of targeted RSV symptoms by Day 15 for participants with symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time.For participants who completed or discontinued study by Day 15 without symptom alleviation (censored),time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15 | 3.2 (2.9 to 4.0) | 3.9 (2.7 to 4.9) |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | 13.5 | 16.2 |
Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point up to the date of the last dose of study drug plus 30 days. The Division of AIDS (DAIDS) Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1: mild, Grade 2: moderate, Grade 3: severe, and Grade 4: potentially life-threatening. Percentage are rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities | 59.5 | 57.5 |
A serious adverse event (SAEs) is defined as an event that, at any dose, results in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentage was rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants Who Experienced Serious Adverse Events | 0 | 1.4 |
TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.
| percentage of participants | Obeldesivir | Placebo |
|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation | 0 | 1.4 |
RiiQ and targeted RSV symptoms are defined in Outcome Measure #1. Each symptom is rated on scale of None, Mild, Moderate, \& Severe. Sustained alleviation of targeted RSV symptoms was defined similarly to alleviation of targeted RSV symptoms but for 3 consecutive assessments. Time to sustained alleviation of targeted RSV symptoms by Day 15 for participants with sustained symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed or discontinued study by Day 15 without sustained symptom alleviation (censored), time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to Sustained Alleviation of Targeted RSV Symptoms as Measured by RiiQ Through Day 15 | 3.7 (2.9 to 5.0) | 4.0 (3.0 to 6.0) |
RiiQ is defined in Outcome Measure #1. Lower Respiratory Tract (LRT) symptoms included cough, expectoration, shortness of breath, and wheezing. Based on RiiQ, RSV-related LRTI was defined as \>=2 of the following symptoms, 1 of which must be reported as at least 'moderate' severity: new or increased cough, new or increased wheezing, new or increased shortness of breath, new or increased expectoration and participant has not met alleviation endpoints. The time to RSV-related LRTI by Day 29 for participants with RSV-related LRTI, was calculated as date/time of meeting LRTI definition minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without RSV-related LRTI (censored), time was calculated as last date/time on which RiiQ was assessed minus the first dose date/time.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to RSV-Related Lower Respiratory Tract Infection (LRTI) Through Day 29 | NA (NA to NA) | NA (NA to NA) |
RSV-related hospitalization is defined as ≥ 24 hours of acute care for a reason related to RSV, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with RSV. RSV relatedness was determined by investigator. KM estimates were used in analysis.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to RSV-Related Hospitalization or All-Cause Death Through Day 29 | NA (NA to NA) | NA (NA to NA) |
Medically attended visits (MAV) are defined as any interactions with health care professionals other than study staff or designees, including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. RSV relatedness was determined by the investigator. KM estimates were used in analysis.
| days | Obeldesivir | Placebo |
|---|---|---|
| Time to RSV-Related Medically Attended Visit or All-Cause Death Through Day 29 | NA (NA to NA) | NA (NA to NA) |
The RSV viral load results were obtained from UTM (universal transport medium) nasal swab samples collected at Baseline.
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| RSV Viral Load At Baseline | 5.33 ± 1.553 | 5.58 ± 1.762 |
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 3.
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| Change From Baseline in RSV Viral Load Through Day 3 | -1.25 ± 0.275 | -1.34 ± 0.261 |
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 5.
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| Change From Baseline in RSV Viral Load Through Day 5 | -2.41 ± 0.244 | -1.64 ± 0.238 |
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 7.
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| Change From Baseline in RSV Viral Load Through Day 7 | -2.80 ± 0.185 | -2.69 ± 0.186 |
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 10.
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| Change From Baseline in RSV Viral Load Through Day 10 | -3.13 ± 0.156 | -2.77 ± 0.162 |
The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 15.
| log10 copies/mL | Obeldesivir | Placebo |
|---|---|---|
| Change From Baseline in RSV Viral Load Through Day 15 | -3.15 ± 0.118 | -3.21 ± 0.121 |
AUCtau is defined as area under the plasma concentration-time curve during a dosing interval.
| h*ng/mL | Obeldesivir |
|---|---|
| Pharmacokinetic (PK) Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir | 23300 ± 7860 |
Ctrough is defined as the concentration at the end of the dosing interval.
| ng/mL | Obeldesivir |
|---|---|
| PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir | 865 ± 475 |
Cmax is defined as the maximum observed concentration of drug in plasma.
| ng/mL | Obeldesivir |
|---|---|
| Day 1 | 5560 ± 2500 |
| Day 5 | 3740 ± 1890 |
Collected over All-Cause Mortality: Up to Day 121; Adverse Events: Up to 5 days plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obeldesivir | 0/75 (0%) | 0/74 (0%) | 0/74 (0%) |
| Placebo | 0/75 (0%) | 1/74 (1.4%) | 0/74 (0%) |
| Event | Obeldesivir | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 0/74 | 1/74 |
The Safety Analysis Set included all randomized participants who took at least 1 dose of study drug.
| Age, Categorical(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 52 | 48 | 100 |
| >=65 years | 21 | 26 | 47 |
| Age, Continuous(years) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Mean | 54 ± 16.9 | 55 ± 16.4 | 54 ± 16.6 |
| Sex: Female, Male(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Female | 42 | 40 | 82 |
| Male | 32 | 34 | 66 |
| Ethnicity (NIH/OMB)(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 51 | 57 | 108 |
| Not Hispanic or Latino | 23 | 17 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 6 | 15 |
| White | 62 | 67 | 129 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| United States | 74 | 74 | 148 |
| Respiratory Syncytial Virus (RSV) Viral Load in Universal Transport Medium (UTM)(log10 copies/mL) | Obeldesivir | Placebo | Total |
|---|---|---|---|
| Mean | 5.03 ± 1.703 | 4.84 ± 2.029 | 4.93 ± 1.879 |
Showing the first 100 of 121 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2024 to primary completion in May 2025, 6 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obeldesivir
Respiratory Syncytial Virus Infections →